Shopping Cart 0
Cart Subtotal
AED 0

Global Erectile Dysfunction Drugs Market 2018-2024

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 16515
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Global Erectile Dysfunction Drugs Market-Drivers, Opportunities, Trends, and Forecasts: 2018-2024

Overview

Erectile dysfunction (ED) refers to the condition in which a male finds it difficult to get or maintain a firm enough erection to be able to have sex or other sexual activities. However, ED is of concern only if the person is not satisfied with his sexual performance on a regular basis. There are many treatments available for ED and most of individuals find a solution that work for them. One such solution is oral therapy and it is considered a standard method of treatment. For cases where the oral therapy don't work, individuals look out for alternatives or substitutes.

To evaluate the overall prevalence and determine the severity of ED across the globe, meta-analysis helps to determine the rationale for understanding the number of men around the globe effected with ED. The research is based on many assumptions. The data analysis below will highlight the key aspects.

Market Scenario

The leading pharma players have seen a slowdown in sales due to patent loss. Taking advantage of this situation, many small companies are making generic drugs for erectile dysfunction. Popular drugs such as Viagra, Cialis and Levitra that stand in the top three positions have lost their market share and few drugs are going to lose their respective shares by 2020. Therefore, there will be a decline in the market and global companies will look for mergers and acquisitions with new entrant to hold their potential in the market.

The market is growing at a rapid pace and is expected to grow at a rapid rate in the emerging countries. Factors such as increasing lifestyle diseases and smoking population, growing aging population, favorable reimbursement, and technological advancements in product development are driving the growth of the erectile dysfunction market. However, lack of awareness about the disease, stringent regulatory approval procedures, and risk associated with the procedure are hampering the growth of the market. The main unmet need in the market is endoleaking, which increases the mortality rate among patients.

Key Players:

The market is dominated by Pfizer, Eli Lilly, Bayer, Meda Pharmaceuticals (Mylan N.V), Apricus Biosciences, and VIVUS. These pharmaceutical companies have the maximum revenue generation in the global erectile dysfunction drugs market.

Market Analysis: The Global Erectile Dysfunction Drugs Market is estimated to witness a CAGR of -9.3% during the forecast period 2018-2024. The market is analyzed based on two segments namely product type and regions.

Regional Analysis: In terms of regions, the market is dominated by North America. However, this region is the most effected due to loss of patents. Further, many small and mid-sized companies have already started developing ED products that are overlapping with the patent expiry of some ED drugs in 2018.

In terms of technology, the European companies are targeting to develop safe and efficient drugs that have less risk and complications associated with the previous branded drugs. Europe is expected to see a moderate negative growth and is expected to have a high number of patent application for CE mark that is followed by North America as NHS has increased its expenditure from USD 145.14 billion (2016/2017) to USD 148.68 billion (2018/2019).

Latin America and APAC are the most focused and fastest growing regions; although having negative growth, the market will have vast opportunities for this segment as most of the countries in these regions are focusing towards increased healthcare expenditure from their respective governments. This will enable the ED affected male population to understand and learn about the problem and overcome the social stigma to augment early prevention and cure. Also, these regions have witnessed substantial growth in medical technology, especially countries such as Brazil, China, India, Mexico, Indonesia, Iran, South Korea, Nigeria, and South Africa.

Competitive Analysis: The global erectile dysfunction drugs market has immense growth opportunities in both developed and developing regions. The patent expiry and development of ED drugs by many small, local, and regional players have disrupted the market size. Most of the companies have received patent drug information and have started developing generic drugs, which are almost in the final stages of completion. This means that most of the pure play vendors have already started research and development on ED drugs and is waiting for the date to coincide with the expiry of the patented drugs in the market. As a result, the major decline in the market is due to the introduction of generic drugs in the market. The fall of leading brands in the market has seen a decline since past few years. For instance, Viagra by Pfizer saw a drastic decline from USD 1,297 million in 2015 to USD 823 million in 2017. This fall in revenue has slowed down the sales of branded products in the market. The market has significant competition and possesses a strong financial incentive for the development of new and generic drugs for treating ED. Some of the leading drugs have given their rights for developing generic drugs. However, there are some companies that still have their product and are planning to come up with adjacent products that will increase their sales in the coming years. The most prominent brands in the market right now are Sildenafil citrate (marketed and sold by Pfizer as Viagra), Tadalafil (marketed and sold by Eli Lilly as Cialis), Vardenafil (marketed and sold by GlaxoSmith-Kline as Levitra), and Avanafil (sold in the US by Metuchen Pharmaceuticals, LLC as Stendra and sold in Europe and New Zealand by The Menarini Group as Spedra).

 

 

 

Benefits: The report provides complete details about the usage and adoption rate of erectile dysfunction drugs for the treatment of ED. Thus, the key stakeholders will find detailed information about the major trends, drivers, investments, vertical player's initiatives, and government initiatives toward the urology segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding business in this market.

Key Stakeholders:

 

READ MORE

Table Of Content

Scope

Table of Contents

1 Industry Outlook

1.1 Industry Overview

1.2 Erectile dysfunction

1.3 Industry Trends

1.4 Patient demographics

1.5 PESTLE Analysis

2 Report Outline

2.1 Report Scope

2.2 Report Summary

2.3 Research Methodology

2.4 Report Assumptions

3 Market Snapshot

3.1 Total Addressable Market (TAM)

3.2 Segmented Addressable Market (SAM)

3.3 Related Markets

3.4 Regulatory Bodies & Standards

3.5 Clinical trials and ethical issues at different phases of research

3.6 Government Spending and Initiatives

3.7 Porter 5 (Five) Forces

4 Market Characteristics

4.1 Evolution

4.2 Market Segmentation

4.3 Market Dynamics

4.3.1 Drivers

4.3.1.1 Increase in incidence of chronic disorders affecting erection in men

4.3.1.2 Increase prevalence of ED

4.3.1.3 Rise in elderly population

4.3.1.4 Lowering healthcare costs

4.3.1.5 Access quality healthcare

4.3.2 Restraints

4.3.2.1 Complications with ED drugs

4.3.2.2 Patents expiration and entry of new generics

4.3.2.3 Alternative and Substitutes oral drug therapy

4.3.3 Opportunities

4.3.3.1 Focusing on R&D activities

4.3.3.2 Upcoming pipeline drugs

4.3.3.3 Increase awareness and commercial advertisement for ED

4.3.3.4 Stem cell therapy

4.3.4 DRO-Impact Analysis

5 Trends, Roadmap and Projects

5.1 Market Trends & Impact

5.2 Technology Roadmap

6 Early diagnosis can prevent permanent erectile dysfunction

6.1 Overview

7 Meta-Analysis

7.1 ED treatment options

7.2 Future of ED

8 Buying criteria

9 Regions

9.1.1.1 Overview

9.1.2 North America

9.1.2.1 Market Overview:

9.1.3 Europe

9.1.3.1 Market Overview:

9.1.4 APAC

9.1.4.1 Market Overview:

9.1.5 Rest of the World

9.1.5.1 Market Overview:

10 Competitive Landscape

10.1 Competitor Comparison Analysis

11 Vendor Profiles

11.1 Pfizer

11.1.1 Overview

11.1.2 Business unit

11.1.3 Geographic Presence

11.1.4 Business Focus

11.1.5 SWOT Analysis

11.1.6 Business Strategies

11.2 Eli Lilly & Company Ltd

11.2.1 Overview

11.2.2 Business Focus

11.2.3 SWOT Analysis

11.2.4 Business Strategies

11.3 Bayer AG

11.3.1 Overview

11.3.2 Business Unit

11.3.3 Geographic Presence

11.3.4 Business Focus

11.3.5 SWOT Analysis

11.3.6 Business Strategy

11.4 Apricus Biosciences, Inc.

11.4.1 Overview

11.4.2 Business Unit

11.4.3 Geographic Presence

11.4.4 Business Focus

11.4.5 SWOT Analysis

11.4.6 Business Strategy

11.5 Mylan N.V. (Meda Pharmaceuticals Inc.)

11.5.1 Overview

11.5.2 Business Unit

11.5.3 Geographic Presence

11.5.4 Business Focus

11.5.5 SWOT Analysis

11.5.6 Business Strategy

11.6 VIVUS, Inc

11.6.1 Overview

11.6.2 Business Unit

11.6.3 Geographic Presence

11.6.4 Business Focus

11.6.5 SWOT Analysis

11.6.6 Business Strategy

12 Companies to Watch for

12.1 Aquestive Therapeutics

12.1.1 Overview

12.1.2 Aquestive Therapeutics: Key highlights

12.1.3 Aquestive Therapeutics: Key news

12.1.4 Aquestive Therapeutics: Erectile dysfunction offering

12.2 Astellas Pharma Inc

12.2.1 Overview

12.2.2 Astellas Pharma: Key highlights

12.2.3 Astellas Pharma: Key news

12.2.4 Astellas Pharma: Erectile dysfunction offering

12.3 BIOLAB FARMACEUTICA

12.3.1 Overview

12.3.2 BIOLAB FARMACEUTICA: Key highlights

12.3.3 BIOLAB FARMACEUTICA: Key news

12.3.4 BIOLAB FARMACEUTICA: Erectile dysfunction offering

12.4 Biopharm GmbH

12.4.1 Overview

12.4.2 Biopharm GmbH: Key highlights

12.4.3 Biopharm GmbH: Key news

12.4.4 Biopharm GmbH: Erectile dysfunction offering

12.5 Futura Medical plc

12.5.1 Overview

12.5.2 Futura Medical: Key highlights

12.5.3 Futura Medical: Key news

12.5.4 Futura Medical: Erectile dysfunction offering (pipeline products)

12.6 iX Biopharma Ltd.

12.6.1 Overview

12.6.2 iX Biopharma Ltd.: Key highlights

12.6.3 iX Biopharma Ltd.: Key news

12.6.4 iX Biopharma Ltd.: Erectile dysfunction offering (pipeline products)

12.7 SK Chemicals Co., Ltd.

12.7.1 Overview

12.7.2 SK Chemicals Co., Ltd.: Key highlights

12.7.3 SK Chemicals Co., Ltd: Key news

12.7.4 SK Chemicals Co., Ltd: Erectile dysfunction offering

13 Other prominent vendors

Annexure

Acronyms

 


List Of Figure

Tables

 

TABLE 1 HISTORICAL TREND OF ED VOLUNTEERS IN DIFFERENT PHASES 26

TABLE 2 ERECTILE DYSFUNCTION CLINICAL TRIALS IN THE US SPREAD ACROSS THE GLOBE IN 2017 27

TABLE 3 PIPELINE SNAPSHOT IN KEY THERAPY AREAS 27

TABLE 4 ETHICAL ISSUES FACED BY VARIOUS RESEARCH INSTITUTES AND LABS AT DIFFERENT PHASES 30

TABLE 5 STEM CELL RESEARCH POLICIES IN AMERICAS 30

TABLE 6 STEM CELL RESEARCH POLICIES IN EUROPE 31

TABLE 7 STEM CELL RESEARCH POLICIES IN APAC 31

TABLE 8 VIAGRA SALES 36

TABLE 9 CIALIS SALES 37

TABLE 10 LEVITRA SALES 38

TABLE 11 STENDRA/SPEDRA SALES 38

TABLE 12 MEN AND ERECTILE DYSFUNCTION STATISTICS 42

TABLE 13 RATE OF ERECTILE DYSFUNCTION AT DIFFERENT AGE GROUPS 51

TABLE 14 OBSERVATIONAL STUDY PERFORMED ON CHINA AND INDIA 52

TABLE 15 ERECTION HARDNESS SCORE (EHS) 54

TABLE 16 GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET REVENUE BY REGIONS FORECAST, 2018-2024 (USD MILLION) 60

TABLE 17 DRO (NORTH AMERICA) 62

TABLE 18 DRO (EUROPE) 65

TABLE 19 DRO (APAC) 68

TABLE 20 DRO (REST OF THE WORLD) 71

TABLE 21 COMPETITIVE STRUCTURE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION MARKET 2017 74

TABLE 22 COMPETITIVE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET 76

TABLE 23 PFIZER, INC.: PRODUCT OFFERINGS 77

TABLE 24 PFIZER INC.: RECENT DEVELOPMENTS 77

TABLE 25 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 82

TABLE 26 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 82

TABLE 27 BAYER AG: OFFERINGS 87

TABLE 28 BAYER AG: RECENT DEVELOPMENTS 87

TABLE 29 APRICUS BIOSCIENCES, INC.: OFFERINGS 93

TABLE 30 APRICUS BIOSCIENCES, INC.: RECENT DEVELOPMENTS 93

TABLE 31 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): OFFERINGS 98

TABLE 32 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): RECENT DEVELOPMENTS 98

TABLE 33 VIVUS, INC: OFFERINGS 103

TABLE 34 VIVUS, INC: RECENT DEVELOPMENTS 103

TABLE 35 AQUESTIVE THERAPEUTICS: SNAPSHOT 109

TABLE 36 ASTELLAS PHARMA INC.: SNAPSHOT 110

TABLE 37 BIOLAB FARMACEUTICA: SNAPSHOT 111

TABLE 38 BIOPHARM GMBH: SNAPSHOT 113

TABLE 39 FUTURA MEDICAL PLC: SNAPSHOT 114

TABLE 40 IX BIOPHARMA LTD.: SNAPSHOT 115

TABLE 41 SK CHEMICALS CO. LTD.: SNAPSHOT 116

 


List Of Table

Tables

 

TABLE 1 HISTORICAL TREND OF ED VOLUNTEERS IN DIFFERENT PHASES 26

TABLE 2 ERECTILE DYSFUNCTION CLINICAL TRIALS IN THE US SPREAD ACROSS THE GLOBE IN 2017 27

TABLE 3 PIPELINE SNAPSHOT IN KEY THERAPY AREAS 27

TABLE 4 ETHICAL ISSUES FACED BY VARIOUS RESEARCH INSTITUTES AND LABS AT DIFFERENT PHASES 30

TABLE 5 STEM CELL RESEARCH POLICIES IN AMERICAS 30

TABLE 6 STEM CELL RESEARCH POLICIES IN EUROPE 31

TABLE 7 STEM CELL RESEARCH POLICIES IN APAC 31

TABLE 8 VIAGRA SALES 36

TABLE 9 CIALIS SALES 37

TABLE 10 LEVITRA SALES 38

TABLE 11 STENDRA/SPEDRA SALES 38

TABLE 12 MEN AND ERECTILE DYSFUNCTION STATISTICS 42

TABLE 13 RATE OF ERECTILE DYSFUNCTION AT DIFFERENT AGE GROUPS 51

TABLE 14 OBSERVATIONAL STUDY PERFORMED ON CHINA AND INDIA 52

TABLE 15 ERECTION HARDNESS SCORE (EHS) 54

TABLE 16 GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET REVENUE BY REGIONS FORECAST, 2018-2024 (USD MILLION) 60

TABLE 17 DRO (NORTH AMERICA) 62

TABLE 18 DRO (EUROPE) 65

TABLE 19 DRO (APAC) 68

TABLE 20 DRO (REST OF THE WORLD) 71

TABLE 21 COMPETITIVE STRUCTURE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION MARKET 2017 74

TABLE 22 COMPETITIVE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET 76

TABLE 23 PFIZER, INC.: PRODUCT OFFERINGS 77

TABLE 24 PFIZER INC.: RECENT DEVELOPMENTS 77

TABLE 25 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 82

TABLE 26 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 82

TABLE 27 BAYER AG: OFFERINGS 87

TABLE 28 BAYER AG: RECENT DEVELOPMENTS 87

TABLE 29 APRICUS BIOSCIENCES, INC.: OFFERINGS 93

TABLE 30 APRICUS BIOSCIENCES, INC.: RECENT DEVELOPMENTS 93

TABLE 31 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): OFFERINGS 98

TABLE 32 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): RECENT DEVELOPMENTS 98

TABLE 33 VIVUS, INC: OFFERINGS 103

TABLE 34 VIVUS, INC: RECENT DEVELOPMENTS 103

TABLE 35 AQUESTIVE THERAPEUTICS: SNAPSHOT 109

TABLE 36 ASTELLAS PHARMA INC.: SNAPSHOT 110

TABLE 37 BIOLAB FARMACEUTICA: SNAPSHOT 111

TABLE 38 BIOPHARM GMBH: SNAPSHOT 113

TABLE 39 FUTURA MEDICAL PLC: SNAPSHOT 114

TABLE 40 IX BIOPHARMA LTD.: SNAPSHOT 115

TABLE 41 SK CHEMICALS CO. LTD.: SNAPSHOT 116

 

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Pfizer, Eli Lilly, Bayer, Meda Pharmaceuticals (Mylan N.V), Apricus Biosciences, and VIVUS

Global Erectile Dysfunction Drugs Market-Drivers, Opportunities, Trends, and Forecasts: 2018-2024

Overview

Erectile dysfunction (ED) refers to the condition in which a male finds it difficult to get or maintain a firm enough erection to be able to have sex or other sexual activities. However, ED is of concern only if the person is not satisfied with his sexual performance on a regular basis. There are many treatments available for ED and most of individuals find a solution that work for them. One such solution is oral therapy and it is considered a standard method of treatment. For cases where the oral therapy don't work, individuals look out for alternatives or substitutes.

To evaluate the overall prevalence and determine the severity of ED across the globe, meta-analysis helps to determine the rationale for understanding the number of men around the globe effected with ED. The research is based on many assumptions. The data analysis below will highlight the key aspects.

Market Scenario

The leading pharma players have seen a slowdown in sales due to patent loss. Taking advantage of this situation, many small companies are making generic drugs for erectile dysfunction. Popular drugs such as Viagra, Cialis and Levitra that stand in the top three positions have lost their market share and few drugs are going to lose their respective shares by 2020. Therefore, there will be a decline in the market and global companies will look for mergers and acquisitions with new entrant to hold their potential in the market.

The market is growing at a rapid pace and is expected to grow at a rapid rate in the emerging countries. Factors such as increasing lifestyle diseases and smoking population, growing aging population, favorable reimbursement, and technological advancements in product development are driving the growth of the erectile dysfunction market. However, lack of awareness about the disease, stringent regulatory approval procedures, and risk associated with the procedure are hampering the growth of the market. The main unmet need in the market is endoleaking, which increases the mortality rate among patients.

Key Players:

The market is dominated by Pfizer, Eli Lilly, Bayer, Meda Pharmaceuticals (Mylan N.V), Apricus Biosciences, and VIVUS. These pharmaceutical companies have the maximum revenue generation in the global erectile dysfunction drugs market.

Market Analysis: The Global Erectile Dysfunction Drugs Market is estimated to witness a CAGR of -9.3% during the forecast period 2018-2024. The market is analyzed based on two segments namely product type and regions.

Regional Analysis: In terms of regions, the market is dominated by North America. However, this region is the most effected due to loss of patents. Further, many small and mid-sized companies have already started developing ED products that are overlapping with the patent expiry of some ED drugs in 2018.

In terms of technology, the European companies are targeting to develop safe and efficient drugs that have less risk and complications associated with the previous branded drugs. Europe is expected to see a moderate negative growth and is expected to have a high number of patent application for CE mark that is followed by North America as NHS has increased its expenditure from USD 145.14 billion (2016/2017) to USD 148.68 billion (2018/2019).

Latin America and APAC are the most focused and fastest growing regions; although having negative growth, the market will have vast opportunities for this segment as most of the countries in these regions are focusing towards increased healthcare expenditure from their respective governments. This will enable the ED affected male population to understand and learn about the problem and overcome the social stigma to augment early prevention and cure. Also, these regions have witnessed substantial growth in medical technology, especially countries such as Brazil, China, India, Mexico, Indonesia, Iran, South Korea, Nigeria, and South Africa.

Competitive Analysis: The global erectile dysfunction drugs market has immense growth opportunities in both developed and developing regions. The patent expiry and development of ED drugs by many small, local, and regional players have disrupted the market size. Most of the companies have received patent drug information and have started developing generic drugs, which are almost in the final stages of completion. This means that most of the pure play vendors have already started research and development on ED drugs and is waiting for the date to coincide with the expiry of the patented drugs in the market. As a result, the major decline in the market is due to the introduction of generic drugs in the market. The fall of leading brands in the market has seen a decline since past few years. For instance, Viagra by Pfizer saw a drastic decline from USD 1,297 million in 2015 to USD 823 million in 2017. This fall in revenue has slowed down the sales of branded products in the market. The market has significant competition and possesses a strong financial incentive for the development of new and generic drugs for treating ED. Some of the leading drugs have given their rights for developing generic drugs. However, there are some companies that still have their product and are planning to come up with adjacent products that will increase their sales in the coming years. The most prominent brands in the market right now are Sildenafil citrate (marketed and sold by Pfizer as Viagra), Tadalafil (marketed and sold by Eli Lilly as Cialis), Vardenafil (marketed and sold by GlaxoSmith-Kline as Levitra), and Avanafil (sold in the US by Metuchen Pharmaceuticals, LLC as Stendra and sold in Europe and New Zealand by The Menarini Group as Spedra).

 

 

 

Benefits: The report provides complete details about the usage and adoption rate of erectile dysfunction drugs for the treatment of ED. Thus, the key stakeholders will find detailed information about the major trends, drivers, investments, vertical player's initiatives, and government initiatives toward the urology segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding business in this market.

Key Stakeholders:

 

READ MORE

Scope

Table of Contents

1 Industry Outlook

1.1 Industry Overview

1.2 Erectile dysfunction

1.3 Industry Trends

1.4 Patient demographics

1.5 PESTLE Analysis

2 Report Outline

2.1 Report Scope

2.2 Report Summary

2.3 Research Methodology

2.4 Report Assumptions

3 Market Snapshot

3.1 Total Addressable Market (TAM)

3.2 Segmented Addressable Market (SAM)

3.3 Related Markets

3.4 Regulatory Bodies & Standards

3.5 Clinical trials and ethical issues at different phases of research

3.6 Government Spending and Initiatives

3.7 Porter 5 (Five) Forces

4 Market Characteristics

4.1 Evolution

4.2 Market Segmentation

4.3 Market Dynamics

4.3.1 Drivers

4.3.1.1 Increase in incidence of chronic disorders affecting erection in men

4.3.1.2 Increase prevalence of ED

4.3.1.3 Rise in elderly population

4.3.1.4 Lowering healthcare costs

4.3.1.5 Access quality healthcare

4.3.2 Restraints

4.3.2.1 Complications with ED drugs

4.3.2.2 Patents expiration and entry of new generics

4.3.2.3 Alternative and Substitutes oral drug therapy

4.3.3 Opportunities

4.3.3.1 Focusing on R&D activities

4.3.3.2 Upcoming pipeline drugs

4.3.3.3 Increase awareness and commercial advertisement for ED

4.3.3.4 Stem cell therapy

4.3.4 DRO-Impact Analysis

5 Trends, Roadmap and Projects

5.1 Market Trends & Impact

5.2 Technology Roadmap

6 Early diagnosis can prevent permanent erectile dysfunction

6.1 Overview

7 Meta-Analysis

7.1 ED treatment options

7.2 Future of ED

8 Buying criteria

9 Regions

9.1.1.1 Overview

9.1.2 North America

9.1.2.1 Market Overview:

9.1.3 Europe

9.1.3.1 Market Overview:

9.1.4 APAC

9.1.4.1 Market Overview:

9.1.5 Rest of the World

9.1.5.1 Market Overview:

10 Competitive Landscape

10.1 Competitor Comparison Analysis

11 Vendor Profiles

11.1 Pfizer

11.1.1 Overview

11.1.2 Business unit

11.1.3 Geographic Presence

11.1.4 Business Focus

11.1.5 SWOT Analysis

11.1.6 Business Strategies

11.2 Eli Lilly & Company Ltd

11.2.1 Overview

11.2.2 Business Focus

11.2.3 SWOT Analysis

11.2.4 Business Strategies

11.3 Bayer AG

11.3.1 Overview

11.3.2 Business Unit

11.3.3 Geographic Presence

11.3.4 Business Focus

11.3.5 SWOT Analysis

11.3.6 Business Strategy

11.4 Apricus Biosciences, Inc.

11.4.1 Overview

11.4.2 Business Unit

11.4.3 Geographic Presence

11.4.4 Business Focus

11.4.5 SWOT Analysis

11.4.6 Business Strategy

11.5 Mylan N.V. (Meda Pharmaceuticals Inc.)

11.5.1 Overview

11.5.2 Business Unit

11.5.3 Geographic Presence

11.5.4 Business Focus

11.5.5 SWOT Analysis

11.5.6 Business Strategy

11.6 VIVUS, Inc

11.6.1 Overview

11.6.2 Business Unit

11.6.3 Geographic Presence

11.6.4 Business Focus

11.6.5 SWOT Analysis

11.6.6 Business Strategy

12 Companies to Watch for

12.1 Aquestive Therapeutics

12.1.1 Overview

12.1.2 Aquestive Therapeutics: Key highlights

12.1.3 Aquestive Therapeutics: Key news

12.1.4 Aquestive Therapeutics: Erectile dysfunction offering

12.2 Astellas Pharma Inc

12.2.1 Overview

12.2.2 Astellas Pharma: Key highlights

12.2.3 Astellas Pharma: Key news

12.2.4 Astellas Pharma: Erectile dysfunction offering

12.3 BIOLAB FARMACEUTICA

12.3.1 Overview

12.3.2 BIOLAB FARMACEUTICA: Key highlights

12.3.3 BIOLAB FARMACEUTICA: Key news

12.3.4 BIOLAB FARMACEUTICA: Erectile dysfunction offering

12.4 Biopharm GmbH

12.4.1 Overview

12.4.2 Biopharm GmbH: Key highlights

12.4.3 Biopharm GmbH: Key news

12.4.4 Biopharm GmbH: Erectile dysfunction offering

12.5 Futura Medical plc

12.5.1 Overview

12.5.2 Futura Medical: Key highlights

12.5.3 Futura Medical: Key news

12.5.4 Futura Medical: Erectile dysfunction offering (pipeline products)

12.6 iX Biopharma Ltd.

12.6.1 Overview

12.6.2 iX Biopharma Ltd.: Key highlights

12.6.3 iX Biopharma Ltd.: Key news

12.6.4 iX Biopharma Ltd.: Erectile dysfunction offering (pipeline products)

12.7 SK Chemicals Co., Ltd.

12.7.1 Overview

12.7.2 SK Chemicals Co., Ltd.: Key highlights

12.7.3 SK Chemicals Co., Ltd: Key news

12.7.4 SK Chemicals Co., Ltd: Erectile dysfunction offering

13 Other prominent vendors

Annexure

Acronyms

 


List Of Figure

Tables

 

TABLE 1 HISTORICAL TREND OF ED VOLUNTEERS IN DIFFERENT PHASES 26

TABLE 2 ERECTILE DYSFUNCTION CLINICAL TRIALS IN THE US SPREAD ACROSS THE GLOBE IN 2017 27

TABLE 3 PIPELINE SNAPSHOT IN KEY THERAPY AREAS 27

TABLE 4 ETHICAL ISSUES FACED BY VARIOUS RESEARCH INSTITUTES AND LABS AT DIFFERENT PHASES 30

TABLE 5 STEM CELL RESEARCH POLICIES IN AMERICAS 30

TABLE 6 STEM CELL RESEARCH POLICIES IN EUROPE 31

TABLE 7 STEM CELL RESEARCH POLICIES IN APAC 31

TABLE 8 VIAGRA SALES 36

TABLE 9 CIALIS SALES 37

TABLE 10 LEVITRA SALES 38

TABLE 11 STENDRA/SPEDRA SALES 38

TABLE 12 MEN AND ERECTILE DYSFUNCTION STATISTICS 42

TABLE 13 RATE OF ERECTILE DYSFUNCTION AT DIFFERENT AGE GROUPS 51

TABLE 14 OBSERVATIONAL STUDY PERFORMED ON CHINA AND INDIA 52

TABLE 15 ERECTION HARDNESS SCORE (EHS) 54

TABLE 16 GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET REVENUE BY REGIONS FORECAST, 2018-2024 (USD MILLION) 60

TABLE 17 DRO (NORTH AMERICA) 62

TABLE 18 DRO (EUROPE) 65

TABLE 19 DRO (APAC) 68

TABLE 20 DRO (REST OF THE WORLD) 71

TABLE 21 COMPETITIVE STRUCTURE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION MARKET 2017 74

TABLE 22 COMPETITIVE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET 76

TABLE 23 PFIZER, INC.: PRODUCT OFFERINGS 77

TABLE 24 PFIZER INC.: RECENT DEVELOPMENTS 77

TABLE 25 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 82

TABLE 26 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 82

TABLE 27 BAYER AG: OFFERINGS 87

TABLE 28 BAYER AG: RECENT DEVELOPMENTS 87

TABLE 29 APRICUS BIOSCIENCES, INC.: OFFERINGS 93

TABLE 30 APRICUS BIOSCIENCES, INC.: RECENT DEVELOPMENTS 93

TABLE 31 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): OFFERINGS 98

TABLE 32 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): RECENT DEVELOPMENTS 98

TABLE 33 VIVUS, INC: OFFERINGS 103

TABLE 34 VIVUS, INC: RECENT DEVELOPMENTS 103

TABLE 35 AQUESTIVE THERAPEUTICS: SNAPSHOT 109

TABLE 36 ASTELLAS PHARMA INC.: SNAPSHOT 110

TABLE 37 BIOLAB FARMACEUTICA: SNAPSHOT 111

TABLE 38 BIOPHARM GMBH: SNAPSHOT 113

TABLE 39 FUTURA MEDICAL PLC: SNAPSHOT 114

TABLE 40 IX BIOPHARMA LTD.: SNAPSHOT 115

TABLE 41 SK CHEMICALS CO. LTD.: SNAPSHOT 116

 


List Of Table

Tables

 

TABLE 1 HISTORICAL TREND OF ED VOLUNTEERS IN DIFFERENT PHASES 26

TABLE 2 ERECTILE DYSFUNCTION CLINICAL TRIALS IN THE US SPREAD ACROSS THE GLOBE IN 2017 27

TABLE 3 PIPELINE SNAPSHOT IN KEY THERAPY AREAS 27

TABLE 4 ETHICAL ISSUES FACED BY VARIOUS RESEARCH INSTITUTES AND LABS AT DIFFERENT PHASES 30

TABLE 5 STEM CELL RESEARCH POLICIES IN AMERICAS 30

TABLE 6 STEM CELL RESEARCH POLICIES IN EUROPE 31

TABLE 7 STEM CELL RESEARCH POLICIES IN APAC 31

TABLE 8 VIAGRA SALES 36

TABLE 9 CIALIS SALES 37

TABLE 10 LEVITRA SALES 38

TABLE 11 STENDRA/SPEDRA SALES 38

TABLE 12 MEN AND ERECTILE DYSFUNCTION STATISTICS 42

TABLE 13 RATE OF ERECTILE DYSFUNCTION AT DIFFERENT AGE GROUPS 51

TABLE 14 OBSERVATIONAL STUDY PERFORMED ON CHINA AND INDIA 52

TABLE 15 ERECTION HARDNESS SCORE (EHS) 54

TABLE 16 GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET REVENUE BY REGIONS FORECAST, 2018-2024 (USD MILLION) 60

TABLE 17 DRO (NORTH AMERICA) 62

TABLE 18 DRO (EUROPE) 65

TABLE 19 DRO (APAC) 68

TABLE 20 DRO (REST OF THE WORLD) 71

TABLE 21 COMPETITIVE STRUCTURE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION MARKET 2017 74

TABLE 22 COMPETITIVE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET 76

TABLE 23 PFIZER, INC.: PRODUCT OFFERINGS 77

TABLE 24 PFIZER INC.: RECENT DEVELOPMENTS 77

TABLE 25 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 82

TABLE 26 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 82

TABLE 27 BAYER AG: OFFERINGS 87

TABLE 28 BAYER AG: RECENT DEVELOPMENTS 87

TABLE 29 APRICUS BIOSCIENCES, INC.: OFFERINGS 93

TABLE 30 APRICUS BIOSCIENCES, INC.: RECENT DEVELOPMENTS 93

TABLE 31 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): OFFERINGS 98

TABLE 32 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): RECENT DEVELOPMENTS 98

TABLE 33 VIVUS, INC: OFFERINGS 103

TABLE 34 VIVUS, INC: RECENT DEVELOPMENTS 103

TABLE 35 AQUESTIVE THERAPEUTICS: SNAPSHOT 109

TABLE 36 ASTELLAS PHARMA INC.: SNAPSHOT 110

TABLE 37 BIOLAB FARMACEUTICA: SNAPSHOT 111

TABLE 38 BIOPHARM GMBH: SNAPSHOT 113

TABLE 39 FUTURA MEDICAL PLC: SNAPSHOT 114

TABLE 40 IX BIOPHARMA LTD.: SNAPSHOT 115

TABLE 41 SK CHEMICALS CO. LTD.: SNAPSHOT 116

 

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Pfizer, Eli Lilly, Bayer, Meda Pharmaceuticals (Mylan N.V), Apricus Biosciences, and VIVUS

chat_bubbleLet's Chat